A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, GLOBAL STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH DURVALUMAB AND CARBOPLATIN VERSUS PEMBROLIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS (AVANZAR)

Registry ID

D926NC00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2024-01-24

Last update

2022-11-03

Conditions

• LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER
• NON-SMALL CELL LUNG CANCER - CACHEXIA (NSCLC-C)

Related clinical trials

• ROSETTA LUNG-201: A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE 3 STUDY OF PUMITAMIG MONOTHERAPY COMPARED TO DURVALUMAB IN PARTICIPANTS WITH UNRESECTABLE STAGE III NSCLC WITHOUT PROGRESSION AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION THERAPY
• A PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN COMPARED TO STANDARD OF CARE IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER AFTER PROGRESSION ON A THIRD-GENERATION EGFR TKI - ANDROMETA-LUNG-713
• A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIRMONERTINIB COMPARED WITH INVESTIGATOR’S CHOICE OF OSIMERTINIB OR AFATINIB AS FIRST-LINE TREATMENT IN PARTICIPANTS WHO HAVE LOCALLY ADVANCED OR METASTATIC NON-SMALLCELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR P-LOOP AND ALPHA C-HELIX COMPRESSING (PACC) UNCOMMON MUTATIONS (ALPACCA)
• A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
• A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON¿SMALL CELL LUNG CANCER
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE STUDY OF DATOPOTAMAB DERUXTECAN OR DOCETAXEL IN PREVIOUSLY TREATED TROP2-POSITIVE ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG17)

View on source registry